
## CLAIMS

WHAT IS CLAIMED IS:

1. A compound of Formula (II):




(II),

or a pharmaceutically acceptable salt or solvate thereof, wherein:

$R^1$ is selected from $C_{3-12}$ carbocycle and 3- to 12-membered heterocycle, each of which is optionally substituted with one or more $R^{20}$;

$L^1$ is 5- to 20-membered heterocycle optionally substituted with one or more $R^{20}$;

$L^2$ is selected from a bond, $C_{1-4}$ alkylene, 2- to 4-membered heteroalkylene, -O-, -N($R^{19}$)-, -C(O)-, -S-, -$S(O)_2$-, -S(O)-, -P(O)$R^{19}$-, -N($R^{19}$)$S(O)_2$-, -N($R^{19}$)S(O)-, -N($R^{19}$)P(O)$R^{19}$-, -$S(O)_2$N($R^{19}$)-, -S(O)N($R^{19}$)-, -P(O)$R^{19}$N($R^{19}$)-, -$OS(O)_2$-, -OS(O)-, -OP(O)$R^{19}$-, -$S(O)_2$O-, -S(O)O-, and -P(O)$R^{19}$O-, wherein $C_{1-4}$ alkylene and 2- to 4-membered heteroalkylene are optionally substituted with one, two, or three $R^{20}$;

$L^3$ and $R^2$, together with the atoms to which they are attached, form 3- to 8-membered monocyclic heterocycloalkyl, $C_{3-8}$ monocyclic cycloalkyl, 7- to 12-membered spirocyclic heterocycloalkyl, or 7- to 12-membered fused bicyclic heterocycloalkyl, each of which is optionally substituted with one, two, or three substituents selected from halogen, -OH, -CN, $C_{1-6}$ alkyl, $C_{3-6}$ cycloalkyl, -O($C_{1-6}$ alkyl), and -O($C_{3-6}$ cycloalkyl), wherein $C_{1-6}$ alkyl, $C_{3-6}$ cycloalkyl, -O($C_{1-6}$ alkyl), and -O($C_{3-6}$ cycloalkyl) are optionally substituted with one, two, or three substituents selected from halogen, -OH, -CN, $C_{1-3}$ alkyl, $C_{1-3}$ haloalkyl, $C_{3-6}$ cycloalkyl, -O($C_{1-3}$ alkyl), and -O($C_{1-3}$ haloalkyl);

$L^3$ and $R^6$, together with the atoms to which they are attached, form 4- to 8-membered monocyclic heterocycloalkyl, 7- to 12-membered spirocyclic heterocycloalkyl, or 7- to 12-membered fused bicyclic heterocycloalkyl, each of which is optionally substituted with one, two, or three substituents selected from halogen, -OH, -CN, $C_{1-6}$ alkyl, $C_{3-6}$ cycloalkyl, -O($C_{1-6}$ alkyl), and -O($C_{3-6}$ cycloalkyl), wherein $C_{1-6}$ alkyl, $C_{3-6}$ cycloalkyl, -O($C_{1-6}$ alkyl), and -O($C_{3-6}$ cycloalkyl) are optionally substituted with one, two, or three substituents selected from halogen, -OH, -CN, $C_{1-3}$ alkyl, $C_{1-3}$ haloalkyl, $C_{3-6}$ cycloalkyl, -O($C_{1-3}$ alkyl), and -O($C_{1-3}$ haloalkyl), and wherein the 4- to 8-membered monocyclic heterocycloalkyl formed by $L^3$ and $R^6$ is not piperazine; or


$R^2$ and $R^6$, together with the atoms to which they are attached, form 3- to 8-membered monocyclic heterocycloalkyl optionally substituted with one, two, or three substituents selected from halogen, -OH, -CN, $C_{1-6}$ alkyl, $C_{3-6}$ cycloalkyl, -O($C_{1-6}$ alkyl), and -O($C_{3-6}$ cycloalkyl), wherein $C_{1-6}$ alkyl, $C_{3-6}$ cycloalkyl, -O($C_{1-6}$ alkyl), and -O($C_{3-6}$ cycloalkyl) are optionally substituted with one, two, or three substituents selected from halogen, -OH, -CN, $C_{1-3}$ alkyl, $C_{1-3}$ haloalkyl, $C_{3-6}$ cycloalkyl, -O($C_{1-3}$ alkyl), and -O($C_{1-3}$ haloalkyl), and wherein $L^3$ is a bond;

$R^2$ is selected from halogen, -CN, $C_{1-6}$ alkyl, and $C_{3-6}$ cycloalkyl, or $R^2$ and $R^3$, together with the carbon atom to which they are attached, form $C_{3-6}$ cycloalkyl, wherein $C_{1-6}$ alkyl and $C_{3-6}$ cycloalkyl are optionally substituted with one, two, or three substituents selected from halogen, -CN, $C_{1-6}$ alkyl, $C_{1-6}$ haloalkyl, $C_{3-6}$ cycloalkyl, -O($C_{1-6}$ alkyl), and -O($C_{1-6}$ haloalkyl);

$R^3$ is selected from hydrogen, halogen, -CN, $C_{1-6}$ alkyl, and $C_{3-6}$ cycloalkyl, wherein $C_{1-6}$ alkyl and $C_{3-6}$

cycloalkyl are optionally substituted with one, two, or three substituents selected from halogen, -CN, $C_{1-6}$ alkyl, $C_{1-6}$ haloalkyl, $C_{3-6}$ cycloalkyl, -O($C_{1-6}$ alkyl), and -O($C_{1-6}$ haloalkyl);

$R^4$, $R^5$, and $R^6$ are each independently selected from hydrogen, halogen, -CN, $C_{1-6}$ alkyl, and $C_{3-6}$ cycloalkyl, or $R^4$ and $R^5$, together with the carbon atom to which they are attached, form $C_{3-6}$ cycloalkyl, wherein $C_{1-6}$ alkyl and $C_{3-6}$ cycloalkyl are optionally substituted with one, two, or three substituents selected from halogen, -CN, $C_{1-6}$ alkyl, $C_{1-6}$ haloalkyl, $C_{3-6}$ cycloalkyl, -O($C_{1-6}$ alkyl), and -O($C_{1-6}$ haloalkyl);

$R^7$ is selected from ;

$R^8$ and $R^9$ are each independently selected from hydrogen, halogen, -CN, $C_{1-6}$ alkyl, and $C_{3-6}$ cycloalkyl, wherein $C_{1-6}$ alkyl and $C_{3-6}$ cycloalkyl are optionally substituted with one, two, or three substituents selected from halogen, -CN, $C_{1-6}$ alkyl, -O($C_{1-6}$ alkyl), and -O($C_{1-6}$ haloalkyl);

$R^{19}$ is independently selected at each occurrence from hydrogen, -CN, $C_{1-6}$ alkyl, $C_{3-6}$ carbocycle, 3- to 6-membered heterocycle, -OH, -O($C_{1-6}$ alkyl), and -O($C_{1-6}$ haloalkyl);

$R^{20}$ is independently selected at each occurrence from halogen, oxo, -CN, $C_{1-6}$ alkyl, $C_{2-6}$ alkenyl, $C_{2-6}$ alkynyl, 2- to 6-membered heteroalkyl, 2- to 6-membered heteroalkenyl, 2- to 6-membered heteroalkynyl, -$C_{0-6}$ alkyl-($C_{3-12}$ carbocycle), -(2- to 6-membered heteroalkyl)-($C_{3-12}$ carbocycle), -$C_{0-6}$ alkyl-(3- to 12-membered heterocycle), -(2- to 6-membered heteroalkyl)-(3- to 12-membered heterocycle), -$OR^{22}$, -$SR^{22}$, -$N(R^{22})(R^{23})$, =$NR^{22}$, =$C(R^{21})_2$, -$C(O)OR^{22}$, -$OC(O)N(R^{22})(R^{23})$, -$N(R^{22})C(O)N(R^{22})(R^{23})$, -$N(R^{22})C(O)OR^{22}$, -$N(R^{22})S(O)_2R^{22}$, -$C(O)R^{22}$, -$S(O)R^{22}$, -$OC(O)R^{22}$, -$C(O)N(R^{22})(R^{23})$, -$C(O)C(O)N(R^{22})(R^{23})$, -$N(R^{22})C(O)R^{22}$, -$S(O)_2R^{22}$, -$S(O)(NR^{22})R^{22}$, -$S(O)_2N(R^{22})(R^{23})$-, -$S(=O)(=NR^{22})N(R^{22})(R^{23})$, and -$OCH_2C(O)OR^{22}$; wherein two $R^{20}$ attached to the same or adjacent atoms optionally join to form $C_{3-12}$ carbocycle or 3- to 12-membered heterocycle; wherein $C_{1-6}$ alkyl, $C_{2-6}$ alkenyl, $C_{2-6}$ alkynyl, 2- to 6-membered heteroalkyl, 2- to 6-membered heteroalkenyl, 2- to 6-membered heteroalkynyl, -$C_{0-6}$ alkyl-($C_{3-12}$ carbocycle), -(2- to 6-membered heteroalkyl)-($C_{3-12}$ carbocycle), -$C_{0-6}$ alkyl-(3- to 12-membered heterocycle), -(2- to 6-membered heteroalkyl)-(3- to 12-membered heterocycle), $C_{3-12}$ carbocycle, and 3- to 12-membered heterocycle are optionally substituted with one or more substituents independently selected from halogen, oxo, -CN, $C_{1-6}$ alkyl, $C_{1-6}$ haloalkyl, $C_{1-6}$ alkoxy, $C_{1-6}$ haloalkoxy, -$OR^{22}$, -$SR^{22}$, -$N(R^{22})(R^{23})$, =$NR^{22}$, =$C(R^{21})_2$, -$C(O)OR^{22}$, -$OC(O)N(R^{22})(R^{23})$, -$N(R^{22})C(O)N(R^{22})(R^{23})$, -$N(R^{22})C(O)OR^{22}$, -$N(R^{22})S(O)_2R^{22}$, -$C(O)R^{22}$, -$S(O)R^{22}$, -$OC(O)R^{22}$, -$C(O)N(R^{22})(R^{23})$, -$C(O)C(O)N(R^{22})(R^{23})$, -$N(R^{22})C(O)R^{22}$, -$S(O)_2R^{22}$, -$S(O)(NR^{22})R^{22}$, -$S(O)_2N(R^{22})(R^{23})$, and -$S(=O)(=NR^{22})N(R^{22})(R^{23})$;

$R^{21}$ is independently selected at each occurrence from hydrogen, halogen, $C_{1-6}$ alkyl, $C_{1-6}$ haloalkyl, -$C_{0-6}$ alkyl-($C_{3-12}$ carbocycle), and -$C_{0-6}$ alkyl-(3- to 12-membered heterocycle), or two $R^{21}$ are taken together with the carbon atom to which they are attached to form $C_{3-12}$ carbocycle or 3- to 12-membered heterocycle, each of which is optionally substituted with one, two, or three substituents independently selected from halogen, $C_{1-3}$ alkyl, $C_{1-3}$ haloalkyl, and -OH;

$R^{22}$ is independently selected at each occurrence from hydrogen, $C_{1-6}$ alkyl, $C_{1-6}$ haloalkyl, -$C_{0-6}$ alkyl-($C_{3-12}$ carbocycle), and -$C_{0-6}$ alkyl-(3- to 12-membered heterocycle); and

$R^{23}$ is independently selected at each occurrence from hydrogen and $C_{1-6}$ alkyl; or $R^{22}$ and $R^{23}$ attached to the same nitrogen atom form 3- to 10 membered heterocycle.


2. The compound, salt, or solvate of claim 1, wherein $L^3$ and $R^2$, together with the atoms to which they are

attached, form 3- to 8-membered monocyclic heterocycloalkyl, $C_{3-8}$ monocyclic cycloalkyl, 7- to 12-membered spirocyclic heterocycloalkyl, or 7- to 12-membered fused bicyclic heterocycloalkyl, each of which is optionally substituted with one, two, or three substituents selected from halogen, -OH, -CN, $C_{1-6}$ alkyl, $C_{3-6}$ cycloalkyl, -O($C_{1-6}$ alkyl), and -O($C_{3-6}$ cycloalkyl), wherein $C_{1-6}$ alkyl, $C_{3-6}$ cycloalkyl, -O($C_{1-6}$ alkyl), and -O($C_{3-6}$ cycloalkyl) are optionally substituted with one, two, or three substituents selected from halogen, -OH, -CN, $C_{1-3}$ alkyl, $C_{1-3}$ haloalkyl, $C_{3-6}$ cycloalkyl, -O($C_{1-3}$ alkyl), and -O($C_{1-3}$ haloalkyl).

3. The compound, salt, or solvate of claim 1, wherein $L^3$ and $R^6$, together with the atoms to which they are attached, form 4- to 8-membered monocyclic heterocycloalkyl, 7- to 12-membered spirocyclic heterocycloalkyl, or 7- to 12-membered fused bicyclic heterocycloalkyl, each of which is optionally substituted with one, two, or three substituents selected from halogen, -OH, -CN, $C_{1-6}$ alkyl, $C_{3-6}$ cycloalkyl, -O($C_{1-6}$ alkyl), and -O($C_{3-6}$ cycloalkyl), wherein $C_{1-6}$ alkyl, $C_{3-6}$ cycloalkyl, -O($C_{1-6}$ alkyl), and -O($C_{3-6}$ cycloalkyl) are optionally substituted with one, two, or three substituents selected from halogen, -OH, -CN, $C_{1-3}$ alkyl, $C_{1-3}$ haloalkyl, $C_{3-6}$ cycloalkyl, -O($C_{1-3}$ alkyl), and -O($C_{1-3}$ haloalkyl), wherein the 4- to 8-membered monocyclic heterocycloalkyl formed by $L^3$ and $R^6$ is not piperazine.

4. The compound, salt, or solvate of claim 1, wherein $R^2$ and $R^6$, together with the atoms to which they are attached, form 3- to 8-membered monocyclic heterocycloalkyl optionally substituted with one, two, or three substituents selected from halogen, -OH, -CN, $C_{1-6}$ alkyl, $C_{3-6}$ cycloalkyl, -O($C_{1-6}$ alkyl), and -O($C_{3-6}$ cycloalkyl), wherein $C_{1-6}$ alkyl, $C_{3-6}$ cycloalkyl, -O($C_{1-6}$ alkyl), and -O($C_{3-6}$ cycloalkyl) are optionally substituted with one, two, or three substituents selected from halogen, -OH, -CN, $C_{1-3}$ alkyl, $C_{1-3}$ haloalkyl, $C_{3-6}$ cycloalkyl, -O($C_{1-3}$ alkyl), and -O($C_{1-3}$ haloalkyl), wherein $L^3$ is a bond.

5. The compound, salt, or solvate of any one of claims 1 to 4, wherein $R^1$ is selected from naphthyl, isoquinolinyl, indazolyl, benzothiazolyl, benzothiophenyl, phenyl, and pyridinyl, each of which is optionally substituted with one or more $R^{20}$.

6. The compound, salt, or solvate of any one of claims 1 to 4, wherein $R^1$ is 


.

7. The compound, salt, or solvate of any one of claims 1 to 6, wherein $L^1$ is 10-membered bicyclic heterocycle substituted with one, two, three, or four $R^{20}$.

8. The compound, salt, or solvate of any one of claims 1 to 7, wherein $L^1$ comprises 1 to 5 nitrogen atoms.


9. The compound, salt, or solvate of any one of claims 1 to 8, wherein $R^2$ is selected from $C_{1-6}$ alkyl and $C_{3-6}$ cycloalkyl.

10. The compound, salt, or solvate of any one of claims 1 to 9, wherein $R^3$ is selected from hydrogen and $C_{1-6}$ alkyl.

11. The compound, salt, or solvate of any one of claims 1 to 10, wherein $R^7$ is .

12. The compound, salt, or solvate of any one of claims 1 to 11, wherein $R^8$ is selected from hydrogen, halogen, $-CH_3$, $-CH_2F$, $-CHF_2$, and $-CF_3$.

13. The compound, salt, or solvate of any one of claims 1 to 12, wherein $R^9$ is selected from hydrogen, halogen, $-CH_3$, $-CH_2F$, $-CHF_2$, and $-CF_3$.


14. The compound, salt, or solvate of claim 11, wherein $R^7$ is .

15. The compound, salt, or solvate of claim 1 wherein:

$R^1$ is selected from naphthyl, isoquinolinyl, indazolyl, benzothiazolyl, benzothiophenyl, phenyl, and pyridinyl, each of which is optionally substituted with one or more $R^{20}$;

$L^1$ is 10-membered bicyclic heterocycle substituted with one, two, three, or four $R^{20}$;

$L^2$ is selected from a bond, $C_{1-3}$ alkylene, and 2- to 3-membered heteroalkylene, wherein $C_{1-3}$ alkylene and 2- to 3-membered heteroalkylene are optionally substituted with one, two, or three $R^{20}$; and

$R^7$ is .


16. A pharmaceutical composition comprising a compound of any one of claims 1 to 15, or a pharmaceutically acceptable salt or solvate thereof, and a pharmaceutically acceptable excipient.

17. A method of modifying a Ras mutant protein, comprising contacting the Ras mutant protein with an effective amount of the compound, salt, or solvate of any one of claims 1 to 15.

18. Use of a compound of any one of claims 1 to 15, or a pharmaceutically acceptable salt or solvate thereof, in the manufacture of a medicament for treating cancer.

19. The use of claim 18, wherein the treatment further comprises an additional agent.

20. A modified Ras protein comprising a compound covalently bonded to one or more amino acid residues of said Ras protein, wherein the modified Ras protein comprises a compound of Formula (I′):

 (I′),

wherein:

the dashed line represents the covalent bond to the amino acid residue;

$R^1$ is selected from $C_{3-12}$ carbocycle and 3- to 12-membered heterocycle, each of which is optionally substituted with one or more $R^{20}$;

$L^1$ is 5- to 20-membered heterocycle optionally substituted with one or more $R^{20}$;

$L^2$ is selected from a bond, $C_{1-4}$ alkylene, 2- to 4-membered heteroalkylene, -O-, -N($R^{19}$)-, -C(O)-, -S-, -$S(O)_2$-, -S(O)-, -P(O)$R^{19}$-, -N($R^{19}$)$S(O)_2$-, -N($R^{19}$)S(O)-, -N($R^{19}$)P(O)$R^{19}$-, -$S(O)_2$N($R^{19}$)-, -S(O)N($R^{19}$)-, -P(O)$R^{19}$N($R^{19}$)-, -$OS(O)_2$-, -OS(O)-, -OP(O)$R^{19}$-, -$S(O)_2$O-, -S(O)O-, and -P(O)$R^{19}$O-, wherein $C_{1-4}$ alkylene and 2- to 4-membered heteroalkylene are optionally substituted with one, two, or three $R^{20}$;

$L^3$ and $R^2$, together with the atoms to which they are attached, form 3- to 8-membered monocyclic heterocycloalkyl, $C_{3-8}$ monocyclic cycloalkyl, 7- to 12-membered spirocyclic heterocycloalkyl, or 7- to 12-membered fused bicyclic heterocycloalkyl, each of which is optionally substituted with one, two, or three substituents selected from halogen, -OH, -CN, $C_{1-6}$ alkyl, $C_{3-6}$ cycloalkyl, -O($C_{1-6}$ alkyl), and -O($C_{3-6}$ cycloalkyl), wherein $C_{1-6}$ alkyl, $C_{3-6}$ cycloalkyl, -O($C_{1-6}$ alkyl), and -O($C_{3-6}$ cycloalkyl) are optionally substituted with one, two, or three substituents selected from halogen, -OH, -CN, $C_{1-3}$ alkyl, $C_{1-3}$ haloalkyl, $C_{3-6}$ cycloalkyl, -O($C_{1-3}$ alkyl), and -O($C_{1-3}$ haloalkyl);

$L^3$ and $R^6$, together with the atoms to which they are attached, form 4- to 8-membered monocyclic heterocycloalkyl, 7- to 12-membered spirocyclic heterocycloalkyl, or 7- to 12-membered fused bicyclic heterocycloalkyl, each of which is optionally substituted with one, two, or three substituents selected from halogen, -OH, -CN, $C_{1-6}$ alkyl, $C_{3-6}$ cycloalkyl, -O($C_{1-6}$ alkyl), and -O($C_{3-6}$ cycloalkyl), wherein $C_{1-6}$ alkyl, $C_{3-6}$ cycloalkyl, -O($C_{1-6}$ alkyl), and -O($C_{3-6}$ cycloalkyl) are optionally substituted with one, two, or three substituents selected from halogen, -OH, -CN, $C_{1-3}$ alkyl, $C_{1-3}$ haloalkyl, $C_{3-6}$ cycloalkyl, -O($C_{1-3}$ alkyl), and -O($C_{1-3}$ haloalkyl), and wherein the 4- to 8-membered monocyclic heterocycloalkyl formed by $L^3$ and $R^6$ is not piperazine; or

$R^2$ and $R^6$, together with the atoms to which they are attached, form 3- to 8-membered monocyclic heterocycloalkyl optionally substituted with one, two, or three substituents selected from halogen, -OH, -CN, $C_{1-6}$ alkyl, $C_{3-6}$ cycloalkyl, -O($C_{1-6}$ alkyl), and -O($C_{3-6}$ cycloalkyl), wherein $C_{1-6}$ alkyl, $C_{3-6}$ cycloalkyl, -O($C_{1-6}$ alkyl), and -O($C_{3-6}$ cycloalkyl) are optionally substituted with one, two, or three substituents selected from halogen, -OH, -CN, $C_{1-3}$ alkyl, $C_{1-3}$ haloalkyl, $C_{3-6}$ cycloalkyl, -O($C_{1-3}$ alkyl), and -O($C_{1-3}$ haloalkyl), and wherein $L^3$ is a bond;

$R^2$ is selected from halogen, -CN, $C_{1-6}$ alkyl, and $C_{3-6}$ cycloalkyl, or $R^2$ and $R^3$, together with the carbon atom to which they are attached, form $C_{3-6}$ cycloalkyl, wherein $C_{1-6}$ alkyl and $C_{3-6}$ cycloalkyl are optionally substituted with one, two, or three substituents selected from halogen, -CN, $C_{1-6}$ alkyl, $C_{1-6}$ haloalkyl, $C_{3-6}$ cycloalkyl, -O($C_{1-6}$ alkyl), and -O($C_{1-6}$ haloalkyl);

$R^3$ is selected from hydrogen, halogen, -CN, $C_{1-6}$ alkyl, and $C_{3-6}$ cycloalkyl, wherein $C_{1-6}$ alkyl and $C_{3-6}$ cycloalkyl are optionally substituted with one, two, or three substituents selected from halogen, -CN, $C_{1-6}$ alkyl, $C_{1-6}$ haloalkyl, $C_{3-6}$ cycloalkyl, -O($C_{1-6}$ alkyl), and -O($C_{1-6}$ haloalkyl);

$R^4$, $R^5$, and $R^6$ are each independently selected from hydrogen, halogen, -CN, $C_{1-6}$ alkyl, and $C_{3-6}$ cycloalkyl, or $R^4$ and $R^5$, together with the carbon atom to which they are attached, form $C_{3-6}$ cycloalkyl, wherein $C_{1-6}$ alkyl and $C_{3-6}$ cycloalkyl are optionally substituted with one, two, or three substituents selected from halogen, -CN, $C_{1-6}$ alkyl, $C_{1-6}$ haloalkyl, $C_{3-6}$ cycloalkyl, -O($C_{1-6}$ alkyl), and -O($C_{1-6}$ haloalkyl);

$R^{19}$ is independently selected at each occurrence from hydrogen, -CN, $C_{1-6}$ alkyl, $C_{3-6}$ carbocycle, 3- to 6-membered heterocycle, -OH, -O($C_{1-6}$ alkyl), and -O($C_{1-6}$ haloalkyl);


$R^{20}$ is independently selected at each occurrence from halogen, oxo, -CN, $C_{1-6}$ alkyl, $C_{2-6}$ alkenyl, $C_{2-6}$ alkynyl, 2- to 6-membered heteroalkyl, 2- to 6-membered heteroalkenyl, 2- to 6-membered heteroalkynyl, -$C_{0-6}$ alkyl-($C_{3-12}$ carbocycle), -(2- to 6-membered heteroalkyl)-($C_{3-12}$ carbocycle), -$C_{0-6}$ alkyl-(3- to 12-membered heterocycle), -(2- to 6-membered heteroalkyl)-(3- to 12-membered heterocycle), -$OR^{22}$, -$SR^{22}$, -$N(R^{22})(R^{23})$, =$NR^{22}$, =$C(R^{21})_2$, -$C(O)OR^{22}$, -$OC(O)N(R^{22})(R^{23})$, -$N(R^{22})C(O)N(R^{22})(R^{23})$, -$N(R^{22})C(O)OR^{22}$, -$N(R^{22})S(O)_2R^{22}$, -$C(O)R^{22}$, -$S(O)R^{22}$, -$OC(O)R^{22}$, -$C(O)N(R^{22})(R^{23})$, -$C(O)C(O)N(R^{22})(R^{23})$, -$N(R^{22})C(O)R^{22}$, -$S(O)_2R^{22}$, -$S(O)(NR^{22})R^{22}$, -$S(O)_2N(R^{22})(R^{23})$-, -$S(=O)(=NR^{22})N(R^{22})(R^{23})$, and -$OCH_2C(O)OR^{22}$; wherein two $R^{20}$ attached to the same or adjacent atoms optionally join to form $C_{3-12}$ carbocycle or 3- to 12-membered heterocycle; wherein $C_{1-6}$ alkyl, $C_{2-6}$ alkenyl, $C_{2-6}$ alkynyl, 2- to 6-membered heteroalkyl, 2- to 6-membered heteroalkenyl, 2- to 6-membered heteroalkynyl, -$C_{0-6}$ alkyl-($C_{3-12}$ carbocycle), -(2- to 6-membered heteroalkyl)-($C_{3-12}$ carbocycle), -$C_{0-6}$ alkyl-(3- to 12-membered heterocycle), -(2- to 6-membered heteroalkyl)-(3- to 12-membered heterocycle), $C_{3-12}$ carbocycle, and 3- to 12-membered heterocycle are optionally substituted with one or more substituents independently selected from halogen, oxo, -CN, $C_{1-6}$ alkyl, $C_{1-6}$ haloalkyl, $C_{1-6}$ alkoxy, $C_{1-6}$ haloalkoxy, -$OR^{22}$, -$SR^{22}$, -$N(R^{22})(R^{23})$, =$NR^{22}$, =$C(R^{21})_2$, -$C(O)OR^{22}$, -$OC(O)N(R^{22})(R^{23})$, -$N(R^{22})C(O)N(R^{22})(R^{23})$, -$N(R^{22})C(O)OR^{22}$, -$N(R^{22})S(O)_2R^{22}$, -$C(O)R^{22}$, -$S(O)R^{22}$, -$OC(O)R^{22}$, -$C(O)N(R^{22})(R^{23})$, -$C(O)C(O)N(R^{22})(R^{23})$, -$N(R^{22})C(O)R^{22}$, -$S(O)_2R^{22}$, -$S(O)(NR^{22})R^{22}$, -$S(O)_2N(R^{22})(R^{23})$, and -$S(=O)(=NR^{22})N(R^{22})(R^{23})$;

$R^{21}$ is independently selected at each occurrence from hydrogen, halogen, $C_{1-6}$ alkyl, $C_{1-6}$ haloalkyl, -$C_{0-6}$ alkyl-($C_{3-12}$ carbocycle), and -$C_{0-6}$ alkyl-(3- to 12-membered heterocycle), or two $R^{21}$ are taken together with the carbon atom to which they are attached to form $C_{3-12}$ carbocycle or 3- to 12-membered heterocycle, each of which is optionally substituted with one, two, or three substituents independently selected from halogen, $C_{1-3}$ alkyl, $C_{1-3}$ haloalkyl, and -OH;

$R^{22}$ is independently selected at each occurrence from hydrogen, $C_{1-6}$ alkyl, $C_{1-6}$ haloalkyl, -$C_{0-6}$ alkyl-($C_{3-12}$ carbocycle), and -$C_{0-6}$ alkyl-(3- to 12-membered heterocycle); and

$R^{23}$ is independently selected at each occurrence from hydrogen and $C_{1-6}$ alkyl; or $R^{22}$ and $R^{23}$ attached to the same nitrogen atom form 3- to 10 membered heterocycle.

21. The modified Ras protein of claim 20, wherein the modified Ras protein is a modified human K-Ras mutant protein comprising a compound covalently bonded to a serine residue having the structure of Formula (I), wherein the serine residue corresponds to position 12 of SEQ ID No. 4:




(I),

and wherein the dashed lines represent bonds between the serine residue and alanine 11 and glycine 13 of the K-Ras mutant protein, respectively.